165 related articles for article (PubMed ID: 23469238)
1. Variable stromal periductular expression of CD34 and smooth muscle actin (SMA) in intraductal carcinoma of the breast.
Catteau X; Simon P; Vanhaeverbeek M; Noël JC
PLoS One; 2013; 8(3):e57773. PubMed ID: 23469238
[TBL] [Abstract][Full Text] [Related]
2. CD34+ fibrocytes in invasive ductal carcinoma, ductal carcinoma in situ, and benign breast lesions.
Barth PJ; Ebrahimsade S; Ramaswamy A; Moll R
Virchows Arch; 2002 Mar; 440(3):298-303. PubMed ID: 11889601
[TBL] [Abstract][Full Text] [Related]
3. Myofibroblastic stromal reaction and lymph node status in invasive breast carcinoma: possible role of the TGF-β1/TGF-βR1 pathway.
Catteau X; Simon P; Noël JC
BMC Cancer; 2014 Jul; 14():499. PubMed ID: 25011545
[TBL] [Abstract][Full Text] [Related]
4. There is more than one kind of myofibroblast: analysis of CD34 expression in benign, in situ, and invasive breast lesions.
Chauhan H; Abraham A; Phillips JR; Pringle JH; Walker RA; Jones JL
J Clin Pathol; 2003 Apr; 56(4):271-6. PubMed ID: 12663638
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathological significance of stromal myofibroblasts in invasive ductal carcinoma of the breast.
Yazhou C; Wenlv S; Weidong Z; Licun W
Tumour Biol; 2004; 25(5-6):290-5. PubMed ID: 15627894
[TBL] [Abstract][Full Text] [Related]
6. Prognostic relevance of the loss of stromal CD34 positive fibroblasts in invasive lobular carcinoma of the breast.
Westhoff CC; Jank P; Jacke CO; Albert US; Ebrahimsade S; Barth PJ; Moll R
Virchows Arch; 2020 Nov; 477(5):717-724. PubMed ID: 32435886
[TBL] [Abstract][Full Text] [Related]
7. The assessment of angiogenesis and fibroblastic stromagenesis in hyperplastic and pre-invasive breast lesions.
Pavlakis K; Messini I; Vrekoussis T; Yiannou P; Keramopoullos D; Louvrou N; Liakakos T; Stathopoulos EN
BMC Cancer; 2008 Apr; 8():88. PubMed ID: 18384688
[TBL] [Abstract][Full Text] [Related]
8. CD34(+) fibrocytes in normal cervical stroma, cervical intraepithelial neoplasia III, and invasive squamous cell carcinoma of the cervix uteri.
Barth PJ; Ramaswamy A; Moll R
Virchows Arch; 2002 Dec; 441(6):564-8. PubMed ID: 12461613
[TBL] [Abstract][Full Text] [Related]
9. Distribution of myofibroblast cells and microvessels around invasive ductal carcinoma of the breast and comparing with the adjacent range of their normal-to-DCIS zones.
Dabiri S; Talebi A; Shahryari J; Meymandi MS; Safizadeh H
Arch Iran Med; 2013 Feb; 16(2):93-9. PubMed ID: 23360631
[TBL] [Abstract][Full Text] [Related]
10. CD34+ fibrocytes in neoplastic and inflammatory pancreatic lesions.
Barth PJ; Ebrahimsade S; Hellinger A; Moll R; Ramaswamy A
Virchows Arch; 2002 Feb; 440(2):128-133. PubMed ID: 11964041
[TBL] [Abstract][Full Text] [Related]
11. CD34(low) and SMA(high) represent stromal signature in uterine cervical cancer and are markers for peritumoral stromal remodeling.
Horn LC; Schreiter C; Canzler A; Leonhardt K; Einenkel J; Hentschel B
Ann Diagn Pathol; 2013 Dec; 17(6):531-5. PubMed ID: 24183311
[TBL] [Abstract][Full Text] [Related]
12. CD34+ fibrocytes, alpha-smooth muscle antigen-positive myofibroblasts, and CD117 expression in the stroma of invasive squamous cell carcinomas of the oral cavity, pharynx, and larynx.
Barth PJ; Schenck zu Schweinsberg T; Ramaswamy A; Moll R
Virchows Arch; 2004 Mar; 444(3):231-4. PubMed ID: 14758552
[TBL] [Abstract][Full Text] [Related]
13. [The value of immunohistochemical expression of Ki-67 and CD34 in differentiating ductal carcinoma in situ from ductal carcinoma in situ-like invasive breast cancer].
Pan XY; Wu JK; Lang ZQ; Qu L; Jiang L
Zhonghua Bing Li Xue Za Zhi; 2022 Sep; 51(9):838-842. PubMed ID: 36097899
[No Abstract] [Full Text] [Related]
14. [Changes of fibroblast immunophenotype and their clinical significance in stromal remodeling of breast tumors].
Hua X; Huang X; Liao Z; Xian Q; Yu L
Zhonghua Zhong Liu Za Zhi; 2014 Nov; 36(11):834-8. PubMed ID: 25620480
[TBL] [Abstract][Full Text] [Related]
15. Myofibroblastic reaction is a common event in metastatic disease of breast carcinoma: a descriptive study.
Catteau X; Simon P; Noël JC
Diagn Pathol; 2014 Oct; 9():196. PubMed ID: 25339428
[TBL] [Abstract][Full Text] [Related]
16. Intraductal carcinoma (ductal carcinoma in situ) of the breast. A comparison of pure noninvasive tumors with those including different proportions of infiltrating carcinoma.
Moriya T; Silverberg SG
Cancer; 1994 Dec; 74(11):2972-8. PubMed ID: 7954261
[TBL] [Abstract][Full Text] [Related]
17. Analysis of stromal signatures in the tumor microenvironment of ductal carcinoma in situ.
Sharma M; Beck AH; Webster JA; Espinosa I; Montgomery K; Varma S; van de Rijn M; Jensen KC; West RB
Breast Cancer Res Treat; 2010 Sep; 123(2):397-404. PubMed ID: 19949854
[TBL] [Abstract][Full Text] [Related]
18. Concurrent and independent genetic alterations in the stromal and epithelial cells of mammary carcinoma: implications for tumorigenesis.
Moinfar F; Man YG; Arnould L; Bratthauer GL; Ratschek M; Tavassoli FA
Cancer Res; 2000 May; 60(9):2562-6. PubMed ID: 10811140
[TBL] [Abstract][Full Text] [Related]
19. Carcinoma in situ of the female breast. A clinico-pathological, immunohistological, and DNA ploidy study.
Ottesen GL
APMIS Suppl; 2003; (108):1-67. PubMed ID: 12874968
[TBL] [Abstract][Full Text] [Related]
20. Is there a low-grade precursor pathway in breast cancer?
King TA; Sakr RA; Muhsen S; Andrade VP; Giri D; Van Zee KJ; Morrow M
Ann Surg Oncol; 2012 Apr; 19(4):1115-21. PubMed ID: 21935747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
